Rapamycin therapy reduced infections and lymph node size in a female child with APDS1
A single female adopted child was diagnosed with Activated phosphoinositide 3-kinase delta syndrome type I (APDS1) following initial misdiagnosis as lymphoma, cystic fibrosis, or primary ciliary dyskinesia. Genetic testing confirmed the diagnosis via a PIK3CD mutation. The patient was treated with rapamycin-targeted therapy in conjunction with compound sulfamethoxazole within a hospital setting.
Treatment resulted in a significant reduction in the frequency of pulmonary infection episodes. Additionally, the size of enlarged lymph nodes in the neck decreased, and overall control of the condition was deemed effective. No specific numerical data, p-values, or confidence intervals were reported for these outcomes.
Regarding safety, adverse events, serious adverse events, discontinuations, and tolerability were not reported in this case report. The patient remained on the regimen during subsequent follow-up without documented interruptions or adverse reactions.
Limitations of this evidence include the small sample size of one patient and the lack of a control group. Consequently, the findings cannot be generalized to the broader population of patients with APDS1. This report aims to enhance clinicians' understanding of this rare primary immunodeficiency disorder rather than to define standard care.